Zhouao P. Zhang

Xuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.

Journal: Autoimmunity

Published: January 27, 2026

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Journal: Science advances

Published: January 02, 2026

Association of plasma ceramide with stroke-associated pneumonia in acute ischemic stroke.

Association of plasma ceramide with stroke-associated pneumonia in acute ischemic stroke.

Journal: Frontiers in immunology

Published: November 05, 2025

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study.

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study.

Journal: Frontiers in immunology

Published: October 23, 2025

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Journal: EClinicalMedicine

Published: August 06, 2025

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.

Journal: Annals of clinical and translational neurology

Published: July 11, 2025

A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.

A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.

Journal: Frontiers in immunology

Published: May 06, 2025

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.

Journal: Frontiers in immunology

Published: February 19, 2025

Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial.

Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 10, 2025

Associations of Inflammatory Markers With Neurological Dysfunction and Prognosis in Patients With Progressive Stroke.

Associations of Inflammatory Markers With Neurological Dysfunction and Prognosis in Patients With Progressive Stroke.

Journal: European journal of neurology

Published: November 26, 2024

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.

Journal: Journal of neuroinflammation

Published: November 14, 2024

Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report.

Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report.

Journal: The neurologist

Published: November 09, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026